AmpliPhi Biosciences (TGEN) Receives Notice of Allowance on Key Patent for its Bacteriophage Therapy to Treat Drug-Resistant Biofilm-based Infections
2/4/2013 10:22:40 AM
RICHMOND Va. & LONDON & SYDNEY--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation [APHB.PK] (“Ampliphi”)(OTCBB:APHB), the anti-infective company focused on developing phage-based therapies to combat the growing threat of antibiotic-resistant infection, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 13/333,684 entitled “Bacteriophage-Containing Therapeutic Agents”. The patent application is important to Ampliphi’s patent estate and developing portfolio, as it covers the use of bacteriophage-based therapy for the treatment of infections caused by the bacteria Pseudomonas aeruginosa associated with biofilms in effective combination with antibiotics. Examples of specific treatment regimens covered include the treatment of human and animal infections resulting from a skin burn or skin wound, a lung infection, an eye, ear or urinary infection or an infection associated with a medical device or implant. Such infections are difficult to treat as they are often resistant to treatment with currently available antibiotics using standard methods of treatment.
comments powered by